EUVIMEDEUVIMED entdecken
Open Access · CC BY-ND 4.0

Analysis of the Effectiveness of the Use of First-Line Anti-Tuberculosis Drugs in Patients with Newly Diagnosed Pulmonary Tuberculosis

H.F. Tverdokhlib

Tuberculosis, Lung Diseases, HIV Infection · 11.05.2026 · (2) · 41-44

DOI: 10.30978/tb2026-2-41 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tuberculosis, Lung Diseases, HIV Infection, online erschienen am 11.05.2026. Verfasst von H.F. Tverdokhlib. Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective — to assess the rate of sputum smear conversion and the frequency of adverse reactions during the use of first-line antimycobacterial drugs (isoniazid, rifampicin, pyrazinamide, ethambutol). Materials and methods. A retrospective study was conducted based on the medical records of 120 pa­­tients with newly diagnosed pulmonary tuberculosis who were treated at the KNP KOR «Kyiv Regional Specialized Medical Center». Results and discussion. The results of the analysis of the effectiveness of standard antimycobacterial therapy in patients with bacteriologically confirmed pulmonary tuberculosis, depending on the presence of comorbid liver disease, are presented, indicating a statistically significant decrease in the effectiveness of antimycobacterial therapy and an increase in the frequency of hepatotoxic reactions in patients with concomitant liver disease. The effectiveness of antimycobacterial therapy after 2 months of treatment was evaluated according to such indicators as the time to cessation of bacterial excretion, the frequency of hepatotoxicity and treatment interruption, which showed higher clinical effectiveness of treatment in the group of patients without comorbid liver disease. Conclusions. The presence of comorbid liver pathology significantly affects the effectiveness of tuberculosis treatment due to changes in the metabolism of antimycobacterial drugs, increased risk of side effects and the development of hepatotoxicity, which leads to treatment interruptions, the formation of drug resistance in mycobacteria and a decrease in the overall effectiveness of antimycobacterial therapy. A comprehensive approach to diagnosis, monitoring and treatment adjustment allows minimising the negative impact of liver dysfunction and improving the success of antimycobacterial therapy.

Zitieren

APA

Tverdokhlib, H. (2026). Analysis of the Effectiveness of the Use of First-Line Anti-Tuberculosis Drugs in Patients with Newly Diagnosed Pulmonary Tuberculosis. Tuberculosis, Lung Diseases, HIV Infection, 41-44. https://doi.org/10.30978/tb2026-2-41

Vancouver

Tverdokhlib H. Analysis of the Effectiveness of the Use of First-Line Anti-Tuberculosis Drugs in Patients with Newly Diagnosed Pulmonary Tuberculosis. Tuberculosis, Lung Diseases, HIV Infection. 2026:41-44. doi:10.30978/tb2026-2-41

BibTeX
@article{Tverdokhlib2026,
  author = {Tverdokhlib, H.F.},
  title = {Analysis of the Effectiveness of the Use of First-Line Anti-Tuberculosis Drugs in Patients with Newly Diagnosed Pulmonary Tuberculosis},
  journal = {Tuberculosis, Lung Diseases, HIV Infection},
  year = {2026},
  number = {2},
  pages = {41--44},
  doi = {10.30978/tb2026-2-41}
}
Kostenlos starten →